A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Latest Information Update: 19 May 2025
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms APHINITY
- Sponsors Roche
Most Recent Events
- 13 May 2025 Results presented in a Genentech Media Release.
- 13 May 2025 According to a Roche media release, announced today statistically significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer.
- 13 May 2025 Results reporting 10 year data presented in a Roche Media Release